PMHNP Certification Exam - American Nurses Credentialing
Center Psychiatric-Mental Health Nurse Practitioner -
2026/2027 Edition - 250 Verified Questions
PMHNP Certification Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest ANCC Guidelines | Graded A+
This comprehensive exam prep document contains 250 verified questions and answers for the PMHNP
Certification Exam by the American Nurses Credentialing Center. Designed for the 2026/2027
academic year, it covers all core content areas including psychiatric assessment, psychopharmacology,
and therapeutic interventions. Each question is accompanied by detailed rationales and distractor
explanations to reinforce learning. Updated to reflect the latest ANCC guidelines, this resource ensures
thorough preparation for certification success.
Key Features:
Psychiatric Assessment and Diagnosis
Psychopharmacology and Medication Management
Therapeutic Communication and Psychotherapy
Patient Safety and Ethical Considerations
Health Promotion and Disease Prevention
Interprofessional Collaboration and Consultation
Updates for 2026:
- Updated to reflect 2026-2027 ANCC test plan changes
- Incorporated new DSM-5-TR diagnostic criteria
- Added questions on telehealth and digital health interventions
- Revised rationales to include latest evidence-based practices
- Enhanced distractor explanations for improved critical thinking
Abstract:
This document provides a rigorous review for the PMHNP Certification Exam, featuring 250 verified questions
that mirror the format and difficulty of the actual ANCC examination. Each question is meticulously crafted to
assess knowledge across the lifespan, from child and adolescent to geriatric psychiatry. The content is organized
into key domains: scientific underpinnings, advanced practice roles, and clinical management. Detailed rationales
elucidate correct answers while distractor analyses clarify common misconceptions. Updated for the 2026-2027
cycle, this resource integrates the latest pharmacogenomic insights and trauma-informed care principles. It serves
as an essential tool for final exam preparation, ensuring candidates demonstrate competency in psychiatric-mental
health nursing practice. The abstract emphasizes the document's alignment with ANCC standards and its utility in
achieving a passing score.
Keywords:
PMHNP certification, ANCC exam prep, psychiatric mental health, nurse practitioner, 250 questions, 2026-2027
edition, verified answers, graded A+
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining the underlying concepts.
Incorrect options are analyzed with distractor explanations to clarify why they are wrong, promoting deeper
understanding and retention.
Compliance Checklist:
Page 1
, Aligned with ANCC PMHNP test plan for 2026-2027
Includes DSM-5-TR diagnostic criteria and updates
Covers all age groups: child, adolescent, adult, geriatric
Integrates evidence-based practice and current guidelines
Provides rationales and distractor explanations for all questions
Suitable for self-assessment and final exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Scientific Underpinnings 1-50 Neurobiology, Psychopharmacology, 20%
Genetics, Epidemiology
Advanced Practice Roles 51-100 Ethics, Legal Issues, Interprofessional 20%
Collaboration, Healthcare Policy
Clinical Management: 101-150 Psychiatric Interview, Mental Status Exam, 20%
Assessment Diagnostic Testing, Differential Diagnosis
Clinical Management: 151-200 Psychotherapy Modalities, Medication 20%
Intervention Management, Crisis Intervention, Patient
Education
Clinical Management: Lifespan 201-250 Child/Adolescent, Adult, Geriatric, Special 20%
Populations
Page 2
,Q1. A patient with treatment-resistant depression has been on venlafaxine 225 mg/day for 8 weeks
with minimal response. The PMHNP considers augmentation with a second-generation
antipsychotic. Which of the following mechanisms best explains why aripiprazole is preferred over
olanzapine in this context, given the patient's comorbid metabolic syndrome?
A. Aripiprazole acts as a partial agonist at D2 receptors, reducing the risk of weight gain and
dyslipidemia compared to olanzapine's strong antagonism.
B. Aripiprazole has higher affinity for 5-HT2A receptors, providing greater antidepressant synergy.
C. Olanzapine is contraindicated with venlafaxine due to risk of serotonin syndrome.
D. Aripiprazole has a shorter half-life, allowing for more flexible dosing adjustments.
Correct Answer: A. Aripiprazole acts as a partial agonist at D2 receptors, reducing the risk of
weight gain and dyslipidemia compared to olanzapine's strong antagonism.
Rationale: Aripiprazole is a partial D2 agonist, which is associated with a lower metabolic side effect
profile (weight gain, dyslipidemia) compared to olanzapine, a full antagonist with high risk for metabolic
syndrome. This makes aripiprazole a safer augmentation choice in patients with existing metabolic issues.
Why Wrong:
B - While aripiprazole does have 5-HT2A antagonism, the primary advantage in metabolic
syndrome is its D2 partial agonism, not 5-HT2A affinity.
C - There is no contraindication between venlafaxine and olanzapine; serotonin syndrome risk is
minimal with this combination.
D - Aripiprazole's half-life is actually long (75 hours), not short; this does not explain metabolic
advantage.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15, 16.
Q2. A 35-year-old patient with generalized anxiety disorder (GAD) has been on buspirone 30
mg/day for 6 weeks with only partial improvement. The patient also has a history of alcohol use
disorder (AUD) and is currently abstinent. Which of the following medication adjustments is MOST
appropriate, considering the comorbidity and pharmacokinetics?
A. Increase buspirone to 60 mg/day, as higher doses are often required for GAD with comorbid AUD.
B. Discontinue buspirone and initiate sertraline 50 mg/day, titrating up to 200 mg/day.
C. Add propranolol 40 mg twice daily as needed for anxiety symptoms.
D. Switch to clonazepam 0.5 mg twice daily to address both anxiety and potential alcohol withdrawal.
Correct Answer: B. Discontinue buspirone and initiate sertraline 50 mg/day, titrating up to 200
mg/day.
Rationale: Sertraline is a first-line SSRI for GAD and is safe in patients with AUD (no disulfiram-like
reaction). Buspirone has limited efficacy in GAD, especially at the current dose. Higher buspirone doses
are not well tolerated and not more effective. Benzodiazepines are relatively contraindicated in AUD due
to abuse potential. Propranolol is not a primary treatment for GAD.
Why Wrong:
A - Buspirone doses above 30 mg/day rarely provide additional benefit and increase side effects; not
recommended.
C - Propranolol is used for situational anxiety or performance anxiety, not for generalized anxiety
disorder.
D - Clonazepam carries high risk of relapse in AUD and is not first-line for GAD, especially with
substance use history.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6.
Page 3
, Q3. A patient with bipolar I disorder, currently stabilized on lithium 900 mg/day (serum level 0.8
mEq/L), presents with acute onset of confusion, tremors, and ataxia. The patient also takes lisinopril
for hypertension. Which of the following is the MOST likely cause of this presentation?
A. Lithium toxicity due to ACE inhibitor-induced reduction in lithium clearance.
B. Lithium-induced serotonin syndrome exacerbated by lisinopril.
C. Hypertensive encephalopathy from lisinopril-lithium interaction.
D. Acute dystonic reaction from lithium alone.
Correct Answer: A. Lithium toxicity due to ACE inhibitor-induced reduction in lithium clearance.
Rationale: ACE inhibitors like lisinopril can decrease renal clearance of lithium, leading to increased
serum lithium levels and toxicity. Symptoms of lithium toxicity include confusion, tremors, and ataxia.
Serotonin syndrome is not associated with this combination, and hypertensive encephalopathy or dystonic
reactions are unlikely.
Why Wrong:
B - Serotonin syndrome requires serotonergic agents; lithium does not typically cause serotonin
syndrome, and lisinopril is not serotonergic.
C - Lisinopril lowers blood pressure, so hypertensive encephalopathy is improbable; the presentation
matches lithium toxicity.
D - Lithium does not cause acute dystonic reactions; those are typical with antipsychotics.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 18.
Q4. A patient with schizophrenia has been maintained on paliperidone palmitate 234 mg
intramuscular monthly. The patient develops significant extrapyramidal symptoms (EPS). The
PMHNP considers switching to another long-acting injectable (LAI). Which of the following LAI
options is MOST appropriate to minimize EPS while maintaining efficacy?
A. Aripiprazole lauroxil, due to its partial D2 agonism.
B. Fluphenazine decanoate, due to its lower potency.
C. Haloperidol decanoate, due to its shorter half-life.
D. Risperidone microspheres, due to its lower D2 occupancy.
Correct Answer: A. Aripiprazole lauroxil, due to its partial D2 agonism.
Rationale: Aripiprazole lauroxil is a partial D2 agonist, which is associated with a lower risk of EPS
compared to full antagonists like paliperidone, risperidone, fluphenazine, or haloperidol. It maintains
antipsychotic efficacy with a more favorable motor side effect profile.
Why Wrong:
B - Fluphenazine is a high-potency first-generation antipsychotic with high risk of EPS, not lower.
C - Haloperidol decanoate also has high EPS risk; shorter half-life does not reduce EPS.
D - Risperidone microspheres are metabolized to paliperidone, so EPS risk is similar; D2 occupancy
is not lower.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5.
Page 4
Center Psychiatric-Mental Health Nurse Practitioner -
2026/2027 Edition - 250 Verified Questions
PMHNP Certification Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest ANCC Guidelines | Graded A+
This comprehensive exam prep document contains 250 verified questions and answers for the PMHNP
Certification Exam by the American Nurses Credentialing Center. Designed for the 2026/2027
academic year, it covers all core content areas including psychiatric assessment, psychopharmacology,
and therapeutic interventions. Each question is accompanied by detailed rationales and distractor
explanations to reinforce learning. Updated to reflect the latest ANCC guidelines, this resource ensures
thorough preparation for certification success.
Key Features:
Psychiatric Assessment and Diagnosis
Psychopharmacology and Medication Management
Therapeutic Communication and Psychotherapy
Patient Safety and Ethical Considerations
Health Promotion and Disease Prevention
Interprofessional Collaboration and Consultation
Updates for 2026:
- Updated to reflect 2026-2027 ANCC test plan changes
- Incorporated new DSM-5-TR diagnostic criteria
- Added questions on telehealth and digital health interventions
- Revised rationales to include latest evidence-based practices
- Enhanced distractor explanations for improved critical thinking
Abstract:
This document provides a rigorous review for the PMHNP Certification Exam, featuring 250 verified questions
that mirror the format and difficulty of the actual ANCC examination. Each question is meticulously crafted to
assess knowledge across the lifespan, from child and adolescent to geriatric psychiatry. The content is organized
into key domains: scientific underpinnings, advanced practice roles, and clinical management. Detailed rationales
elucidate correct answers while distractor analyses clarify common misconceptions. Updated for the 2026-2027
cycle, this resource integrates the latest pharmacogenomic insights and trauma-informed care principles. It serves
as an essential tool for final exam preparation, ensuring candidates demonstrate competency in psychiatric-mental
health nursing practice. The abstract emphasizes the document's alignment with ANCC standards and its utility in
achieving a passing score.
Keywords:
PMHNP certification, ANCC exam prep, psychiatric mental health, nurse practitioner, 250 questions, 2026-2027
edition, verified answers, graded A+
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining the underlying concepts.
Incorrect options are analyzed with distractor explanations to clarify why they are wrong, promoting deeper
understanding and retention.
Compliance Checklist:
Page 1
, Aligned with ANCC PMHNP test plan for 2026-2027
Includes DSM-5-TR diagnostic criteria and updates
Covers all age groups: child, adolescent, adult, geriatric
Integrates evidence-based practice and current guidelines
Provides rationales and distractor explanations for all questions
Suitable for self-assessment and final exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Scientific Underpinnings 1-50 Neurobiology, Psychopharmacology, 20%
Genetics, Epidemiology
Advanced Practice Roles 51-100 Ethics, Legal Issues, Interprofessional 20%
Collaboration, Healthcare Policy
Clinical Management: 101-150 Psychiatric Interview, Mental Status Exam, 20%
Assessment Diagnostic Testing, Differential Diagnosis
Clinical Management: 151-200 Psychotherapy Modalities, Medication 20%
Intervention Management, Crisis Intervention, Patient
Education
Clinical Management: Lifespan 201-250 Child/Adolescent, Adult, Geriatric, Special 20%
Populations
Page 2
,Q1. A patient with treatment-resistant depression has been on venlafaxine 225 mg/day for 8 weeks
with minimal response. The PMHNP considers augmentation with a second-generation
antipsychotic. Which of the following mechanisms best explains why aripiprazole is preferred over
olanzapine in this context, given the patient's comorbid metabolic syndrome?
A. Aripiprazole acts as a partial agonist at D2 receptors, reducing the risk of weight gain and
dyslipidemia compared to olanzapine's strong antagonism.
B. Aripiprazole has higher affinity for 5-HT2A receptors, providing greater antidepressant synergy.
C. Olanzapine is contraindicated with venlafaxine due to risk of serotonin syndrome.
D. Aripiprazole has a shorter half-life, allowing for more flexible dosing adjustments.
Correct Answer: A. Aripiprazole acts as a partial agonist at D2 receptors, reducing the risk of
weight gain and dyslipidemia compared to olanzapine's strong antagonism.
Rationale: Aripiprazole is a partial D2 agonist, which is associated with a lower metabolic side effect
profile (weight gain, dyslipidemia) compared to olanzapine, a full antagonist with high risk for metabolic
syndrome. This makes aripiprazole a safer augmentation choice in patients with existing metabolic issues.
Why Wrong:
B - While aripiprazole does have 5-HT2A antagonism, the primary advantage in metabolic
syndrome is its D2 partial agonism, not 5-HT2A affinity.
C - There is no contraindication between venlafaxine and olanzapine; serotonin syndrome risk is
minimal with this combination.
D - Aripiprazole's half-life is actually long (75 hours), not short; this does not explain metabolic
advantage.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15, 16.
Q2. A 35-year-old patient with generalized anxiety disorder (GAD) has been on buspirone 30
mg/day for 6 weeks with only partial improvement. The patient also has a history of alcohol use
disorder (AUD) and is currently abstinent. Which of the following medication adjustments is MOST
appropriate, considering the comorbidity and pharmacokinetics?
A. Increase buspirone to 60 mg/day, as higher doses are often required for GAD with comorbid AUD.
B. Discontinue buspirone and initiate sertraline 50 mg/day, titrating up to 200 mg/day.
C. Add propranolol 40 mg twice daily as needed for anxiety symptoms.
D. Switch to clonazepam 0.5 mg twice daily to address both anxiety and potential alcohol withdrawal.
Correct Answer: B. Discontinue buspirone and initiate sertraline 50 mg/day, titrating up to 200
mg/day.
Rationale: Sertraline is a first-line SSRI for GAD and is safe in patients with AUD (no disulfiram-like
reaction). Buspirone has limited efficacy in GAD, especially at the current dose. Higher buspirone doses
are not well tolerated and not more effective. Benzodiazepines are relatively contraindicated in AUD due
to abuse potential. Propranolol is not a primary treatment for GAD.
Why Wrong:
A - Buspirone doses above 30 mg/day rarely provide additional benefit and increase side effects; not
recommended.
C - Propranolol is used for situational anxiety or performance anxiety, not for generalized anxiety
disorder.
D - Clonazepam carries high risk of relapse in AUD and is not first-line for GAD, especially with
substance use history.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6.
Page 3
, Q3. A patient with bipolar I disorder, currently stabilized on lithium 900 mg/day (serum level 0.8
mEq/L), presents with acute onset of confusion, tremors, and ataxia. The patient also takes lisinopril
for hypertension. Which of the following is the MOST likely cause of this presentation?
A. Lithium toxicity due to ACE inhibitor-induced reduction in lithium clearance.
B. Lithium-induced serotonin syndrome exacerbated by lisinopril.
C. Hypertensive encephalopathy from lisinopril-lithium interaction.
D. Acute dystonic reaction from lithium alone.
Correct Answer: A. Lithium toxicity due to ACE inhibitor-induced reduction in lithium clearance.
Rationale: ACE inhibitors like lisinopril can decrease renal clearance of lithium, leading to increased
serum lithium levels and toxicity. Symptoms of lithium toxicity include confusion, tremors, and ataxia.
Serotonin syndrome is not associated with this combination, and hypertensive encephalopathy or dystonic
reactions are unlikely.
Why Wrong:
B - Serotonin syndrome requires serotonergic agents; lithium does not typically cause serotonin
syndrome, and lisinopril is not serotonergic.
C - Lisinopril lowers blood pressure, so hypertensive encephalopathy is improbable; the presentation
matches lithium toxicity.
D - Lithium does not cause acute dystonic reactions; those are typical with antipsychotics.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 18.
Q4. A patient with schizophrenia has been maintained on paliperidone palmitate 234 mg
intramuscular monthly. The patient develops significant extrapyramidal symptoms (EPS). The
PMHNP considers switching to another long-acting injectable (LAI). Which of the following LAI
options is MOST appropriate to minimize EPS while maintaining efficacy?
A. Aripiprazole lauroxil, due to its partial D2 agonism.
B. Fluphenazine decanoate, due to its lower potency.
C. Haloperidol decanoate, due to its shorter half-life.
D. Risperidone microspheres, due to its lower D2 occupancy.
Correct Answer: A. Aripiprazole lauroxil, due to its partial D2 agonism.
Rationale: Aripiprazole lauroxil is a partial D2 agonist, which is associated with a lower risk of EPS
compared to full antagonists like paliperidone, risperidone, fluphenazine, or haloperidol. It maintains
antipsychotic efficacy with a more favorable motor side effect profile.
Why Wrong:
B - Fluphenazine is a high-potency first-generation antipsychotic with high risk of EPS, not lower.
C - Haloperidol decanoate also has high EPS risk; shorter half-life does not reduce EPS.
D - Risperidone microspheres are metabolized to paliperidone, so EPS risk is similar; D2 occupancy
is not lower.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5.
Page 4
